Overview

A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Status:
Withdrawn

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if there is an improvement in progression-free survival (length of time during and after treatment in which a patient is living with a disease that does not get worse) when siltuximab is added to VELCADE and dexamethasone in subjects with relapsed or refractory multiple myeloma.

Phase:

Phase 3

Details

Lead Sponsor:

Centocor, Inc.

Treatments:

Antibodies, Monoclonal
BB 1101
Bortezomib
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Siltuximab